274 results about "Low blood sugar level" patented technology

Described herein are methods, devices, and microprocessors useful for predicting a hypoglycemic event in a subject. The hypoglycemic predictive approach described herein utilizes information obtained from a data stream, e.g., frequently obtained glucose values (current and/or predicted), body temperature, and/or skin conductance, to predict incipient hypoglycemic events and to alert the user.

A method, system, and computer program product related to the diagnosis of diabetes, and is directed to predicting the long-term risk of hyperglycemia, and the long-term and short-term risks of severe hypoglycemia in diabetics, based on blood glucose readings collected by a self-monitoring blood glucose device. The method, system, and computer program product pertain directly to the enhancement of existing home blood glucose monitoring devices, by introducing an intelligent data interpretation component capable of predicting both HbA_1c and periods of increased risk of hypoglycemia, and to the enhancement of emerging continuous monitoring devices by the same features. With these predictions the diabetic can take steps to prevent the adverse consequences associated with hyperglycemia and hypoglycemia.

An Adaptive Advisory Control (AA Control) interactive process involving algorithm-based assessment and communication of physiologic and behavioral parameters and patterns assists patients with diabetes with the optimization of their glycemic control. The method and system may uses all available sources of information about the patient; (i) EO Data (e.g. self-monitoring of blood glucose (SMBG) and CMG), (ii) Insulin Data (e.g. insulin pump log files or patient treatment records), and (iii) Patient Self Reporting Data (e.g. self treatment behaviors, meals, and exercise) to: retroactively assess the risk of hypoglycemia, retroactively assess risk-based reduction of insulin delivery, and then report to the patient how a risk-based insulin reduction system would have acted consistently to prevent hypoglycemia.

In one embodiment, the present invention is directed to a communication device that analyzes received utterances and detects when the speaker has a target physical condition.

The invention discloses a natural food additive which belongs to the technical field of food additives. The natural food additive is characterized by comprising the following substances in percentage by weight: 20%-30% of a red bayberry anthocyanin extractive, 10%-20% of a purple sweet potato anthocyanin extractive, 10%-40% of a mulberry anthocyanin extractive, 10%-50% of an okra pectin and polysaccharide extractive, 10%-20% of a folium ginkgo extractive, 0.0005%-0.0008% of selenium yeast, 2%-10% of seaweed meal, and 5%-10% of ganoderma lucidum spore powder. The natural food additive has strong functions of oxidation resistance, aging resistance, fatigue resistance, invigorating the kidney, strengthening Yang, improving immunity and reducing blood sugar, cholesterol and triglyceride. After the natural food additive is detected, the total anthocyanin content is 15%-36%, the total flavone content is 16%-28% and the total phenolic acid content is 18%-29%.

Methods are disclosed for treating a patient with Type 2 diabetes to decrease hypoglycemic episodes and/or to diminish fluctuations in blood glucose outside of the normal range, comprising administering to said patient, in a therapeutically-effective amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. Further disclosed is a method of suppressing appetite in a patient with Type 2 diabetes comprising administering to the subject, in an effective appetite suppressing amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. In preferred embodiments, the food composition is in the form of a bar.

The invention discloses a konjac and moringa oleifera noodle and a processing technique thereof. The konjac and moringa oleifera noodle comprises, by mass, 90-120 parts of flour, 0.1-0.2 part of alkali, 1-2 parts of moringa oleifera powder, 1-3 parts of salt, 1-5 parts of konjac powder and 35-50 parts of water. The processing technique of the konjac and moringa oleifera noodle comprises the steps of material preparation, dough kneading, dough curing, continuous rolling, slicing, drying, slicing, metering and packaging. The konjac and moringa oleifera noodle made with the method is good in surface effect, smooth, bright in color and lustre and free of odor, breakage and twisting are avoided after the noodle is placed in water, the noodle is not sticky to teeth after being eaten, capable of being bitten repeatedly, high in elasticity, good in taste and not spicy, and has the faint scent of konjac and freshness of moringa oleifera. Compared with traditional noodles, the konjac and moringa oleifera noodle has the advantages that the noodle has comprehensive nutrients, and can prevent obesity, reduce blood glucose and blood fat, boost immunity and prevent osteoporosis after being eaten for a long time, and the health-care function is remarkable.

A method, system and related computer program product for tracking the probability of hypoglycemia from routine self-monitoring of blood glucose (SMBG) data in patients with diabetes. A specific bivariate probability distribution of low BG events based jointly on the Low BG Index (LBGI) and the Average Daily Risk Range (ADRR) is used to predict hypoglycemia probability of occurrence from inputted SMBG data. The SMBG data is retrieved from a series of SMBG data of a patient available from the patient's glucose meter and allows tracking of the probability for future hypoglycemia over a predetermined duration, e.g., a 24 or 48 hour period. The tracking includes presentation of visual and/or numerical output, as we construction of hypoglycemia risk trajectories that would enable warning messages for crossing of predefined thresholds, such as 50% likelihood for upcoming hypoglycemia below 50 mg/dl.

The invention belongs to the field of health care foods and specifically relates to compound dendrobium candidum and American ginseng buccal tablets and a preparation method thereof. The method comprises the following steps of: performing ultrafine grinding on dendrobium candidum and American ginseng, taking ultrafine powder of the dendrobium candidum and the American ginseng as raw material, adding resistant starch, a sweetening agent and a bonding agent, preparing wet particles, drying, sizing, finally mixing with a lubricating agent, and then tabletting to get finished products. According to the compound dendrobium candidum and American ginseng buccal tablets prepared by the method disclosed by the invention, the raw material is subject to the ultrafine grinding, various biological active substances in the raw material can be retained to the greatest extent, the biological availability is high, and the dendrobium candidum and the American ginseng are compatible for use, so that the effects of resisting fatigue, nourishing Yin, producing body fluid and the like can be enhanced. The resistant starch is added in the buccal tablets so as to enhance the effects of preventing and treating intestinal diseases, reducing blood sugar and the like; and the compound dendrobium candidum and American ginseng buccal tablets are suitable for more people and more suitable for patients with diabetes for taking, have the characteristics of convenience in carrying, convenience in taking, easiness in control of dosage and the like, and are further in line with simple, convenient and fast consumer demands of modern people.

The invention relates to a drug for reducing blood glucose, regulating blood lipid and treating diabetes mellitus combined with hyperlipidemia and other chronic vascular complications and a preparation method thereof. The drug is total alkaloids which are extracted from traditional Chinese medicine golden thread. The preparation method of the drug comprises the following steps: 1) the golden thread herbal medicine is crushed into coarse powder; 2) 5-10 times of the amount of 60-80 percent ethanol is used for carrying out the reflux extraction of the golden thread coarse powder for 1-3 times by 1-2h/time, the filtration is carried out by times, and filtrates are merged. Golden thread extract is obtained by pressure reduction concentration and drying; 3) the golden thread extract is added in 5 times of the amount of 0.5 percent sulfuric acid for dissolution and filtration, the filtrates are respectively regulated to pH9 by lime milk, filtrated and respectively regulated to pH1-2 by hydrochloric acid, sodium chloride is added to allow the salt content to be 10 percent, and the total alkaloids of the golden thread are obtained by even shaking and still placement. Or the golden thread extract is used for separating and purifying the total alkaloids of the golden thread by macroporous resin method. The drying is carried out, and the total alkaloids of the golden thread are prepared into oral formulation or injection formulation. The drug has prominent efficacy for the diabetes mellitus combined with hyperlipidemia and other chronic vascular complications.

The invention relates to a diet extender capable of restraining a diabetic's blood sugar level from rising after a meal. The diet extender comprises the following components by the weight percentage: 8-97 wt percent of indigestion carbohydrate, 1-10 wt percent of food gum, 1-90 wt percent of saccharide with low blood sugar level generation index, and 1-80 wt percent of flavoring agent. The diet extender capable of restraining the diabetic's blood sugar level from rising after the meal adopts water-soluble dietary fibers and the saccharide with the low blood sugar level generation index as raw materials, and ensures that the metabolism of the diet extender doest not depend on insulin, satiety cannot be increased excessively, normal diet cannot be affected, a diabetic can change a food habit of eating frequently but small meals, and enough energy and microelement are obtained from foods on the basis that the blood sugar level is restrained from rising.

The invention relates to a pharmaceutical composition having alpha-glucosidase inhibition activity, wherein the pharmaceutical composition comprises a flavone compound and an alpha-glucosidase inhibitor, the flavone compound is at least one selected from a monomer such as baicalein, quercetin, luteolin, baicalein-7-O-glucoside and catechin, an organic salt of the monomer, and an inorganic salt of the monomer, and the alpha-glucosidase inhibitor is at least one selected from a monomer such as acarbose, voglibose and miglitol, an organic salt of the monomer, and an inorganic salt of the monomer. According to the present invention, the pharmaceutical composition can effectively reduce postprandial blood glucose, can inhibit the activity of alpha-glucosidase adopting starch, maltose and sucrose as substrates, and less uses the alpha-glucosidase inhibitor, such that the efficacy can be improved, the side effect of the alpha-glucosidase inhibitor can be effectively reduced, and hypoglycemia and other problems easily caused by drug combination are effectively solved.

The invention discloses honeysuckle flower green tea which comprises the following raw materials of honeysuckle flower, green tea, licorice, white sugar and a food additive, wherein the food additive comprises citric acid and sodium citrate. The honeysuckle flower green tea of the invention has functions of refreshing brain, improving immunity, resisting virus, bacteria and inflammation, relieving fatigue, improving metabolism, lowering blood sugar and blood pressure, resisting ageing and cancer, preventing cancer, appetizing and protecting stomach. The honeysuckle flower green tea is golden yellow and has herb aroma and slight taste of traditional Chinese medicine. The honeysuckle flower green tea is sour, sweet and bitter and can be drunk as beverage as well as oral liquid without losing healthcare function thereof.

The invention belongs to the technical field of drugs for treating diabetes and provides a traditional Chinese medicine preparation for treating diabetic complications in order to solve the problem of various complications existing in the process that diabetic patients are treated through orally taking traditional Chinese medicines and western medicines and injecting insulin at present. The traditional Chinese medicine preparation is prepared from mulberry leaves, ginkgo leaves, seabuckthorn leaves, schisandra chinensis, common yam rhizome, chrysanthemum morifolium, bitter gourd, bitter tartary buckwheat, mulberry twig, astragalus, tuckahoe, danshen, radix puerariae, semen cassiae, mulberries, rhizoma alismatis, pseudo-ginseng and rhizoma coptidis according to a certain proportion. The traditional Chinese medicine preparation can be used for slowly reducing blood glucose and effectively preventing and delaying the occurrence and development of diabetic complications, and is remarkable in effect on treating complications caused by diabetes while assisting in reducing the blood glucose and increasing the glucose tolerance; and in addition, the traditional Chinese medicine preparation can be used for softening blood vessels, promoting the microcirculation of blood, regulating the intestine and stomach functions, improving the mental condition and the sleeping quality, effectively reducing the risks for developing the diabetic complications, reducing the economic burdens of patients and improving the physical conditions and living quality of the patients.

Methods and systems are described for controlling a flowrate of insulin infused into the body of a patient. An insulin infusion device infuses insulin into the body of the patient. A first sensor generates blood glucose level (BGL) data indicative of a blood glucose level of the patient. A second sensor generates autonomic nervous system (ANS) data such as heart rate data dependent on at least one parameter of the patient's autonomic nervous system. A data fusion processor receives the BGL data and the ANS data and generates an output alarm signal if a hypoglycaemic event is inferred. A flowrate of insulin of the insulin infusion device may be modified dependent on the output alarm signal.